N-protein vaccine Convacell® is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial

Sevastyan O. Rabdano, Ellina A. Ruzanova, Anastasiya E. Vertyachikh, Valeriya A. Teplykh, Alla B. Emelyanova, German O. Rudakov, Sergei A. Arakelov, Iuliia V. Pletyukhina, Nikita S. Saveliev, Anna A. Lukovenko, Liliya N. Fakhretdinova, Ariana S. Safi, Ekaterina N. Zhirenkina, Irina N. Polyakova, Natalia S. Belozerova, Vladislav V. Klykov, Arina P. Savelieva, Aleksey A. Ekimov, Vadim A. Merkulov, Sergei M. Yudin, Daria S. Kruchko, Igor A. Berzin, Veronika I. Skvortsova, Clinical Trial Group
doi: https://doi.org/10.1101/2024.04.01.24304717

Article Information

doi 
https://doi.org/10.1101/2024.04.01.24304717
History 
  • April 9, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Sevastyan O. Rabdano1,*,
  2. Ellina A. Ruzanova1,
  3. Anastasiya E. Vertyachikh1,
  4. Valeriya A. Teplykh1,
  5. Alla B. Emelyanova1,
  6. German O. Rudakov1,
  7. Sergei A. Arakelov1,
  8. Iuliia V. Pletyukhina1,
  9. Nikita S. Saveliev1,
  10. Anna A. Lukovenko1,
  11. Liliya N. Fakhretdinova1,
  12. Ariana S. Safi1,
  13. Ekaterina N. Zhirenkina1,
  14. Irina N. Polyakova1,
  15. Natalia S. Belozerova1,
  16. Vladislav V. Klykov1,
  17. Arina P. Savelieva1,
  18. Aleksey A. Ekimov1,
  19. Vadim A. Merkulov2,3,
  20. Sergei M. Yudin4,
  21. Daria S. Kruchko5,
  22. Igor A. Berzin5,
  23. Veronika I. Skvortsova5,
  24. Clinical Trial Group†
  1. 1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), St. Petersburg, Russia
  2. 2I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
  3. 3Centre for Evaluation and Control of Finished Pharmaceutical Products, Federal State Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of the Ministry of Health of the Russian Federation, Moscow, Russia
  4. 4Centre for Strategic Planning of FMBA of Russia Federal State Budgetary Institution “Centre for Strategic Planning and Management of Biomedical Health Risks” of the Federal Medical Biological Agency, Moscow, Russia
  5. 5Federal Medical-Biological Agency of Russia, Moscow, Russia
  1. ↵*Corresponding author. Email: sevastyan{at}rabdano.ru. Address: 52, Svobody st., Krasnoe Selo, Saint Petersburg, Russia, 198320.
Back to top
Posted April 09, 2024.
Download PDF

Supplementary Material

Data/Code
Email
N-protein vaccine Convacell® is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
Sevastyan O. Rabdano, Ellina A. Ruzanova, Anastasiya E. Vertyachikh, Valeriya A. Teplykh, Alla B. Emelyanova, German O. Rudakov, Sergei A. Arakelov, Iuliia V. Pletyukhina, Nikita S. Saveliev, Anna A. Lukovenko, Liliya N. Fakhretdinova, Ariana S. Safi, Ekaterina N. Zhirenkina, Irina N. Polyakova, Natalia S. Belozerova, Vladislav V. Klykov, Arina P. Savelieva, Aleksey A. Ekimov, Vadim A. Merkulov, Sergei M. Yudin, Daria S. Kruchko, Igor A. Berzin, Veronika I. Skvortsova, Clinical Trial Group
medRxiv 2024.04.01.24304717; doi: https://doi.org/10.1101/2024.04.01.24304717
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area